Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated response content aligns with the provided alprazolam XR prescribing information excerpts: concomitant opioid risks, abuse/misuse/addiction risks, and dependence/withdrawal risks are explicitly supported by the cited label sections; no contradictions were identified.
Category Scores
Accurate Statements
Concomitant opioid use increases serious CNS/respiratory risks (e.g., profound sedation, respiratory depression, coma, and death) for alprazolam XR, and involves lower dosing/minimum duration and close monitoring.
Supported by Warnings and Precautions 5.1 and Drug Interactions 7.1.
Alprazolam XR has risks of abuse, misuse, and addiction that can lead to overdose or death.
Supported by Warnings and Precautions 5.2.
Continued use can lead to physical dependence, and abrupt discontinuation/rapid reduction may precipitate acute withdrawal reactions that can be life-threatening (e.g., seizures); tapering guidance exists in 2.2.
Supported by Warnings and Precautions 5.3 and Discontinuation/Dosage Reduction 2.2.
Unsupported Statements
Contradictions
Important Omissions
The response provided at audit-time references only general risk elements; it does not explicitly mention all listed example outcomes from 5.1/5.2/5.3 (e.g., 'coma' in the summarized opioid-risk statement, and the detailed duration range of protracted withdrawal) though the core risk categories were correctly supported.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response accurately reflects major on-label boxed warning topics and related withdrawal/tapering guidance for alprazolam XR; no label contradictions were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No substantive misalignment; minor omissions of some detailed examples/ranges from the label were present in the summarized form.
Suggested Improvement
Include all major example outcomes and specific tapering details if a fully comprehensive label-to-response mapping is required (while keeping the discussion limited to what is asked).